GlassScriptPhysician profile
Leonard Spishakoff
NPI 1275597098
$11,492.13
in general payments reported to CMS, 2019-2025
44 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 87% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $747 · 2021: $567 · 2022: $2,395 · 2023: $2,593 · 2024: $2,275 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,316 · Travel and Lodging: $784 · Education: $9.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,315.55 |
| Travel and Lodging | $784.24 |
| Education | $9.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,072.12 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,369.60 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $1,254.61 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,040.43 | 2022-2025 | Caplyta |
| Abbvie INC. | $794.65 | 2019-2025 | Vraylar |
| Lundbeck LLC | $408.74 | 2020-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $365.20 | 2022-2023 | Austedo, Austedo Xr, Uzedy |
| Alkermes, INC. | $353.93 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $320.28 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $313.18 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $276.30 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $263.26 | 2022-2023 | Ingrezza |
| Novo Nordisk INC | $245.90 | 2019-2021 | |
| Indivior INC. | $238.77 | 2019-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $221.56 | 2022-2023 | Quviviq |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Spishakoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.